ADV101 / Advesya - LARVOL DELTA

ADV-101: a novel ADC targeting IL-1RAP, leveraging tumor cell and the tumor microenvironment vulnerabilities for enhanced anti-tumor efficacy (AACR 2025) - "ADV-101 safety was further established in a non-human primate (NHP) dose-range finding toxicity study, showing no severe adverse events up to the highest dose tested (50 mg/kg), together with robust pharmacokinetics data confirming exposure. Altogether, these findings warrant further development to bring ADV-101 to the clinic."

Biomarker • Clinical • Tumor cell • Tumor microenvironment • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Ewing Sarcoma • Head and Neck Cancer • Oncology • Sarcoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • IL1B

ADV101, a first-in-class IL-1RAP ADC demonstrates significant anti-tumor activity in solid tumor models (AACR 2024) - "In vivo efficacy studies in IL-1RAP-positive subcutaneous xenograft tumor models also demonstrated a significant dose-dependent and IL-1RAP antigen-dependent anti-tumor response for both anti-IL-1RAP ADCs. Altogether the robust preclinical data package supports the continued development of ADV101 as a novel targeted ADC therapeutic strategy for a broad spectrum of cancers."

Preclinical • Acute Myelogenous Leukemia • Esophageal Cancer • Ewing Sarcoma • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Leukemia • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor